Structural basis for the complete loss of GSK3β catalytic activity due to R96 mutation investigated by molecular dynamics study

Proteins: Structure, Function and Bioinformatics

Volumn 75, Issue 3, 2009, Pages 671-681

  Zhang, Na ^a,b   Jiang, Yongjun ^a   Zou, Jianwei ^a   Yu, Qingsen ^a   Zhao, Wenna ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Electronic interaction; Glycogen synthesis kinase 3; MM GBSA; Molecular dynamics simulation; Phospho ser

Indexed keywords

ADENOSINE TRIPHOSPHATE; ARGININE; GLYCOGEN SYNTHASE KINASE 3BETA; PHOSPHATE; PHOSPHOSERINE;

ALLOSTERISM; ALPHA HELIX; AMINO ACID SUBSTITUTION; ARTICLE; CATALYSIS; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; ENERGY TRANSFER; ENZYME INACTIVATION; ENZYME MECHANISM; ENZYME STRUCTURE; ENZYME SUBSTRATE COMPLEX; GENE MUTATION; GLYCOGEN SYNTHESIS; MOLECULAR DYNAMICS; MOLECULAR MODEL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; STRUCTURE ANALYSIS; WILD TYPE;

ADENOSINE TRIPHOSPHATE; AMINO ACID SUBSTITUTION; ARGININE; CATALYSIS; CATALYTIC DOMAIN; COMPUTER SIMULATION; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MODELS, MOLECULAR; MUTAGENESIS; MUTATION; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN CONFORMATION; SERINE; STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS; THREONINE;

EID: 66149130737     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.22279     Document Type: Article

References (75)

1. Schenk PW, Snaar-Jagalska BE. Signal perception and transduction: the role of protein kinases. Biochim Biophys Acta 1999;1449:1-24. (Pubitemid 29078546)
2. Cohen P. The regulation of protein function by multisite phosphorylation - a 25-year update. Trends Biochem Sci 2000;25:596-601.
3. Hunter T. Signaling-2000 and beyond. Cell 2000;100:113-127.
4. Johnson LN, Noble MEM, Owen DJ. Active and inactive protein kinases: structural basis for regulation. Cell 1996;85:149-158. (Pubitemid 26118158)
5. Johnson LN, Lewis RJ. Structural basis for control by phosphorylation. Chem Rev 2001;101:2209-2242. (Pubitemid 35373017)
6. Nolen B, Taylor S, Ghosh G. Regulation of protein kinases: controlling activity through activation segment conformation. Mol Cell 2004;15:661-675. (Pubitemid 39194898)
7. Huse M, John K. The conformational plasticity of protein kinases. Cell 2002;109:275-282. (Pubitemid 34606870)
8. Gibbs CS, Zoller MJ. Rational scanning mutagenesis of a protein kinase identifies functional regions involved in catalysis and substrate interactions. J Biol Chem 1991;266:8923-8931. (Pubitemid 21906599)
9. Leon BC, Tsigelny I, Adams JA. Electrostatic environment surrounding the activation loop phosphotyrosine in the oncoprotein v-Fps. Biochemistry 2001;40:10078-10086. (Pubitemid 32800115)
10. Skamnaki VT, Owen DJ, Noble ME, Lowe ED, Lowe G, Oikonomakos NG, Johnson LN. Catalytic mechanism of phosphorylase kinase probed by mutational studies. Biochemistry 1999;38:14718-14730. (Pubitemid 129517615)
11. George S, Rochford JJ, Wolfrum C, Gray SL, Schinner S, Wilson JC, Soos MA, Murgatroyd PR, Williams RM, Acerini CL, Dunger DB, Barford D, Umpleby AM, Wareham NJ, Davies HA, Schafer AJ, Stoffel M, O'Rahilly S, Barroso I. A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science 2004;304:1325-1328. (Pubitemid 38697429)
12. Niefind K, Yde CW, Ermakova I, Issinger O-G. Evolved to be active: sulfate ions define substrate recognition sites of CK2α and emphasise its exceptional role within the CMGC family of eukaryotic protein kinases. J Mol Biol 2007;370:427-438. (Pubitemid 46898435)
13. Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 1990;9:2431-2438. (Pubitemid 20218338)
14. Ali A, Hoeflich KP, Woodgett JR. Glycogen synthase kinase-3: properties, functions, and regulation. Chem Rev 2001;10:2527-2540. (Pubitemid 35373033)
15. Cohen P, Frame S. The renaissance of GSK3. Nat Rev Mol Cell Biol 2001;2:769-776. (Pubitemid 33679839)
16. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multitasking kinase. J Cell Sci 2003;116:1175-1186. (Pubitemid 36410657)
17. Hagit EF. Glycogen synthase kinase-3: an emerging therapeutic target. Trends Mol Med 2002;8:8126-8132.
18. Fram S, Cohen P. GSK3 takes center stage more than 20 years after its discovery. Biochem J 2001;359:1-16. (Pubitemid 32939202)
19. Jope RS, Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 2004;26:95-102. (Pubitemid 38186580)
20. Alonso M, Martinez A. GSK-3 inhibitors: discoveries and developments. Curr Med Chem 2004;11:755-763. (Pubitemid 38380049)
21. Dessalew N, Bharatam PV. Identification of potential glycogen kinase-3 inhibitors by structure based virtual screening. Biophys Chem 2007;128:165-175. (Pubitemid 46860305)
22. Zhang N, Jiang YJ, Zou JW, Zhang B, Jin HX, Wang YH, Yu QS. 3D QSAR for GSK-3β inhibition by indirubin analogues. Eur J Med Chem 2006;41:373-378.
23. Thomas GMA. GSK3-binding peptide from FRAT1 selectively inhibits the GSK3-catalysed phosphorylation of axin and L-catenin. FEBS Lett 1999;458:247-251. (Pubitemid 29428192)
24. Fiol CJ, Mahrenholz AM, Wang Y, Roeske RW, Roach PJ. Formation of protein kinase recognition sites by covalent modification of the substrate, molecular mechanism for the synergistic action of casein kinase II and glycogen synthase kinase 3. J Biol Chem 1987;262:14042-14048.
25. Welsh GI, Proud CG. Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B. Biochem J 1993;294:625-629. (Pubitemid 23286543)
26. Welsh GI, Miller CM, Loughlin AJ, Price NT, Proud CG. Regulation of eukaryotic initiation factor eIF2B: glycogen synthase kinase-3 phosphorylates a conserved serine which undergoes dephosphorylation in response to insulin. FEBS Lett 1998;421:125-130. (Pubitemid 28288076)
27. Yost C, Torres M, Miller JR, Huang E, Kimerlman D, Moon RT. The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev 1996;10:1443-1454. (Pubitemid 26260702)
28. Wang Z, Vogelstein B, Kinzler KW. Phosphorylation of β-catenin at S33, S37 or T41 can occur in the absence of phosphorylation of T45 in colon cancer cells. Cancer Res 2003;63:5234-5235.
29. Dajani R, Fraser E, Roe SM, Yeo M, Good VM, Thompson V, Dale TC, Pear LH. Structural basis for recruitment of glycogen synthase kinase 3b to the axin-APC scaffold complex. EMBO J 2003;22:494-501. (Pubitemid 36193594)
30. Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y, Zhang Z, Liu X, Hem X. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002;108:837-847. (Pubitemid 34327534)
31. Hagen T, Vidal-pulig A. Characterisation of the phosphorylation of β-catenin at the GSK-3 priming site Ser45. Biochem Biophys Res Commun 2002;294:324-328. (Pubitemid 34694097)
32. Ding VW, Chen RH, McCormick F. Differential regulation of glycogen synthase kinase 3β by insulin and Wnt signaling. J Biol Chem 2000;275:32475-32481.
33. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmins BA. Inhibition of glycogen synthase kinase-3by insulin mediated by protein kinase B. Nature 1995;378:785-789. (Pubitemid 26004411)
34. Frame S, Cohen P, Biondi RM. A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol Cell 2001;7:1321-1327. (Pubitemid 32607364)
35. Dajani R, Fraser E, Roe SM, Young N, Good V, Dale TC, Pearl LH. Crystal structure of glycogen synthase kinase 3β: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell 2001;105:721-732.
36. Ter Haar E, Coll JT, Austen DA, Hsiao HM, Swenson L, Jain J. Structure of GSK3β reveals a primed phosphorylation mechanism. Nat Struct Biol 2001;8:593-659 (Pubitemid 32613006)
37. Coghlan MP, Culbert A, Cross DA, Corcoran SL, Yates JW, Pearce NJ, Rausch OL, Murphy GJ, Carter PS, Roxbee Cox, Mills D, Brown MJ, Haigh D, Ward RW, Smith DG, Murray KJ, Reith AD, Holder J. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol 2000;7:793-803.
38. Pap M, Cooper GM. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway. J Biol Chem 1998;273:19929-19932. (Pubitemid 28377539)
39. Bax B, Carter PS, Lewis C, Guy AR, Bridges A, Tanner R, Pettman G, Mannix C, Culbert AA, Brown MJ, Smith DG, Reith AD. The structure of phosphorylated GSK-3β complexed with a peptide FRATtide, that inhibitsβ-catenin phosphorylation. Structure 2001;9:1143-1152. (Pubitemid 34025049)
40. Ung MU, Lu BZ, McCammon JA. E230Q mutation of the catalytic subunit of cAMP-dependent protein kinase affects local structure and the binding of peptide inhibitor. Biopolymers 2006;81:428-439.
41. Zhang N, Jiang YJ, Zou JW, Zhuang SL, Jin HX, Yu QS. Insights into unbinding mechanisms upon two mutations investigated by molecular dynamics study of GSK3α-Axin complex: role of packing hydrophobic residues. Proteins 2007;67:941-949. (Pubitemid 46753941)
42. Bertrand JA, Thieffine S, Vulpetti A, Cristiani C, Valsasina Knapp BS, Kalisz HM, Flocco M. Structural characterization of the GSK-3β active site using selective and non-selective ATP-mimetic inhibitors. J Mol Biol 2003;333:393-407. (Pubitemid 37188580)
43. Sybyl Version 6.8. St. Louis, MO: Tripos Associates Inc.; 2001.
44. Case DA, Darden T, Cheathem TE, III, Simmerling C, Wang JM, Duke RE, Luo R, Merz KM, Wang B, Pearlman DA, Croley M, Brozell S, Tsui V, Gohleke H, Mongan J, Hornak V, Cui GL, Beroza P, Schafmeister C, Caldwell JW, Ross WS, Kollman PA. AMBER, 8. San Francisco: University of California; 2004.
45. Wong SE, Bernacki K, Jacobson M. Competition between intramolecular hydrogen bonds and solvation in phosphorylated peptides: simulations with explicit and implicit solvent. J Phys Chem B 2005;109:5249-5258.
46. Homeyer N, Horn AH, Lanig H, Sticht H. AMBER force field parameters for phosphorylated amino acids in different protonation states: phosphoserine, phosphothreonine, phosphotyrosine and phosphohistidine. J Mol Model 2006;12:281-289. (Pubitemid 43337197)
47. Meagher KL, Redman LT, Carlson HA. Development of polyphosphate parameters for use with the AMBER force field. J Comput Chem 2003;24:1016-1025.
48. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. Comparison of simple potential functions for simulating liquid water. J Chem Phys 1983;79:926-935.
49. Duan Y, Wu C, Chowdhury S, Lee MC, Xiong G, Zhang W, Yang R, Cieplak P, Luo R, Lee T. A point-charge force field for molecular mechanics simulations of proteins. J Comput Chem 2003;24:1999-2012.
50. Berendsen HJC, Postma JPM, Van Gunsteren WF, Di Nol A, Haak JR. Molecular dynamics with coupling to an external bath. J Chem Phys 1984;81:3684-3690.
51. Ryckaert JP, Ciccotti G, Berendsen HJC. Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comput Phys 1977;23:327-341.
52. Darden T, York D, Pedersen L. Particle mesh Ewald: an N log(N) method for Ewald sums in large systems. J Chem Phys 1993;98:10089-10094.
53. Srivivasan J, Cheatham T, III, Cieplak P, Kollman PA, Case DA. Continuum solvent studies of the stability of DNA, RNA, and phosphoramidate-DNA helices J Am Chem Soc 1998;120:9401-9409.
54. Kollman PA, Massova I, Reyes C, Kuhn B, Shuanghong H, Chong L, Lee M, Lee T, Duan Y, Wang W, Donini O, Cieplak P, Srinivasan J, Case DA, Cheatham TE, III. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res 2000;33:889-897.
55. Jayaram B, Sprous D, Beveridge DL. Solvation free energy of biomacromolecules: parameters for a modified generalized born model consistent with the AMBER force field. J Phys Chem B 1998;102:9571-9576. (Pubitemid 128611876)
56. Gilson MK, Sharp KA, Honig BH. Calculating the electrostatic potential of molecules in solution: method and error assessment. J Comput Chem 1987;9:327-335.
57. Feig M, Onufriev A, Lee MS, Im W, Case DA, Brooks CL, III. Performance comparison of generalized born and Poisson methods in the calculation of electrostatic solvation energies for protein structures. J Comput Chem 2004;25:265-284.
58. Weiser J, Shenkin PS, Still WC. Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO). J Comput Chem 1999;20:217-230. (Pubitemid 129653030)
59. Scarsi M, Apostolakis J, Caflisch A. Comparison of a GB solvation model with explicit solvent simulations: potentials of mean force and conformational preferences of alanine dipeptide and 1,2-dichloroethane. J Phys Chem B 1998;102:3637-3641. (Pubitemid 128576692)
60. Wang J, Morin P, Wang W, Kollman PA. Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA. J Am Chem Soc 2001;123:5221-5230. (Pubitemid 32910665)
61. Massova I, Kollman PA. Combined molecular mechanical and continuum solvent approach (MM-PBSA/GBSA) to predict ligand binding. Persp Drug Disc Des 2000;18:113-135. (Pubitemid 30191024)
62. Wang W, Kollman PA. Computational study of protein specificity: the molecular basis of HIV-1 protease drug resistance. Proc Natl Acad Sci USA 2001;98:14937-14942. (Pubitemid 34013948)
63. Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, Zakrzewski VG, Montgomery JA, Jr, Stratmann RE, Burant JC, Dapprich S, Millam JM, Daniels AD, Kudin KN, Strain MC, Farkas O, Tomasi J, Barone V, Cossi M, Cammi R, Mennucci B, Pomelli C, Adamo C, Clifford S, Ochterski J, Petersson GA, Ayala PY, Cui Q, Morokuma K, Malick DK, Rabuck AD, Raghavachari K, Foresman JB, Cioslowski J, Ortiz JV, Stefanov BB, Liu G, Liashenko A, Piskorz P, Komaromi I, Gomperts R, Martin RL, Fox DJ, Keith T, Al-Laham MA, Peng CY, Nanayakkara A, Gonzalez C, Challacombe M, Gill PMW, Johnson BG, Chen W, Wong MW, Andres JL, Head-Gordon M, Replogle ES, Pople JA. Gaussian 03. Wallingford, CT: Gaussian Inc.; 2003.
64. Gallivan JP, Dougherty DA. Cation-pinteractions in structural biology. Proc Natl Acad Sci USA 1999;96:9459-9464.
65. Cox S, Taylor SS. Kinetic analysis of cAMP-dependent protein kinase: mutations at histidine 87 affect peptide binding and pH dependence. Biochemistry 1995;34:16203-16209.
66. Preethi KG, Srinivasan N. Structural modes of stabilization of permissive phosphorylation sites in protein kinases: distinct strategies in Ser/Thr and Tyr kinases A. J Mol Biol 2004;339:1025-1039. (Pubitemid 39303246)
67. Aimes RT, Hemmer W, Taylor SS. Serine-53 at the tip of the glycine-rich loop of cAMP-dependent protein kinase: role in catalysis, P-site specificity, and interaction with inhibitors. Biochemistry 2000;39:8325-8332.
68. Grant B, Hemmer W, Tsigelny I, Adams JA, Taylor SS. Kinetic analyses of mutations in the glycine-rich loop of cAMP-dependent protein kinase. Biochemistry 1998;37:7708-7715. (Pubitemid 28248629)
69. Jin HX, Wu TX, Jiang YJ, Zou JW, Zhuang SL, Mao X, Yu QS. Role of phosphorylated Thr-197 in the catalytic subunit of cAMP-dependent protein kinase. J Mol Struct 2007;805:9-15.
70. Bártová I, Otyepka M, Kr̂îẑ Z, Koĉa J. The mechanism of inhibition of the cyclin-dependent kinase-2 as revealed by the molecular dynamics study on the complex CDK2 with the peptide substrate HHASPRKIVETA. Protein Sci 2005;14:445-451. (Pubitemid 40194597)
71. Bártová I, Otyepka M, Kr̂îẑ Z, Koĉa J. Activation and inhibition of cyclin-dependent kinase-2 by phosphorylation, a molecular dynamics study reveals the functional importance of the glycine-rich loop. Protein Sci 2004;13:1449-1457. (Pubitemid 38669233)
72. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000;289:1938-1942.
73. Mohammadi M, McMahon G, Sun L, Tang C, Hirth P, Yeh BK, Hubbar SR, Schlessinger J. Structures of the tyrosine kinase domain of fibroblastgrowth factor receptor in complex with inhibitors. Science 1997;276:955-960. (Pubitemid 27209095)
74. Hubbard SR, Wei L, Ellis L, Hendrickson WA. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 1994;372:746-754.
75. Barrett CP, Noble MEM. Molecular motions of human Cyclin-dependent kinase 2. J Biol Chem 2005;80:13993-14005. (Pubitemid 40517301)